CN104010641B - 用于治疗淀粉样蛋白病和共核蛋白病的含咖啡因的化合物和组合物 - Google Patents
用于治疗淀粉样蛋白病和共核蛋白病的含咖啡因的化合物和组合物 Download PDFInfo
- Publication number
- CN104010641B CN104010641B CN201280051004.1A CN201280051004A CN104010641B CN 104010641 B CN104010641 B CN 104010641B CN 201280051004 A CN201280051004 A CN 201280051004A CN 104010641 B CN104010641 B CN 104010641B
- Authority
- CN
- China
- Prior art keywords
- disease
- compounds
- amyloid
- synuclein
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IIAPKGOEOXDRLT-UHFFFAOYSA-N CC(C(C1N(C)C([Br]=C)=NC1N1C)=O)C1=O Chemical compound CC(C(C1N(C)C([Br]=C)=NC1N1C)=O)C1=O IIAPKGOEOXDRLT-UHFFFAOYSA-N 0.000 description 1
- DKCNMCHKRXDQBJ-UHFFFAOYSA-N CN(c1c(C(N2C)=O)[n](Cc(cc3)cc(OCc4ccccc4)c3OCc3ccccc3)c([Br]=C)n1)C2=O Chemical compound CN(c1c(C(N2C)=O)[n](Cc(cc3)cc(OCc4ccccc4)c3OCc3ccccc3)c([Br]=C)n1)C2=O DKCNMCHKRXDQBJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552077P | 2011-10-27 | 2011-10-27 | |
| US61/552,077 | 2011-10-27 | ||
| PCT/US2012/059481 WO2013062762A1 (en) | 2011-10-27 | 2012-10-10 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104010641A CN104010641A (zh) | 2014-08-27 |
| CN104010641B true CN104010641B (zh) | 2017-04-12 |
Family
ID=48168320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280051004.1A Expired - Fee Related CN104010641B (zh) | 2011-10-27 | 2012-10-10 | 用于治疗淀粉样蛋白病和共核蛋白病的含咖啡因的化合物和组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9169255B2 (enExample) |
| EP (1) | EP2753333B1 (enExample) |
| JP (1) | JP6095072B2 (enExample) |
| CN (1) | CN104010641B (enExample) |
| AU (1) | AU2012329274B2 (enExample) |
| CA (1) | CA2853633A1 (enExample) |
| WO (1) | WO2013062762A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6527948B2 (ja) | 2014-10-09 | 2019-06-12 | クワントン レイノベント バイオテック カンパニー リミテッド | ヒドロキシプリン化合物及びその応用（ｈｙｄｒｏｘｙｌ ｐｕｒｉｎｅ ｃｏｍｐｏｕｎｄｓ ａｎｄ ａｐｐｌｉｃａｔｉｏｎｓ ｔｈｅｒｅｏｆ） |
| RU2766139C2 (ru) * | 2016-03-11 | 2022-02-08 | Ац Иммуне Са | Бициклические соединения для диагностики и лечения |
| KR102623819B1 (ko) * | 2017-03-27 | 2024-01-10 | 체이스 테라퓨틱스 코포레이션 | 시누클레인병변을 치료하기 위한 조성물 및 방법 |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| EP3920921A4 (en) * | 2019-02-07 | 2022-11-02 | Alsatech, Inc. | POLYVALENT EMOXYPIN DERIVATIVES |
| WO2023023867A1 (en) * | 2021-08-26 | 2023-03-02 | Mcmaster University | Compounds for reducing cholesterol and treating liver and kidney disease |
| CN115997722A (zh) * | 2022-12-26 | 2023-04-25 | 海南大学 | Aβ42-hIAPP共寡聚化物诱导的AD非人灵长类动物模型方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4431000A (en) * | 1999-05-12 | 2000-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| EP1808169B8 (en) * | 1999-12-30 | 2012-07-04 | Proteotech Inc. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| PT1444233E (pt) * | 2001-11-09 | 2011-09-29 | Gilead Palo Alto Inc | Antagonistas de receptor de adenosina a2b |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| WO2004034963A2 (en) * | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| SI2527315T1 (sl) * | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
| CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
-
2012
- 2012-10-10 EP EP12842836.4A patent/EP2753333B1/en not_active Not-in-force
- 2012-10-10 US US14/238,755 patent/US9169255B2/en not_active Expired - Fee Related
- 2012-10-10 WO PCT/US2012/059481 patent/WO2013062762A1/en not_active Ceased
- 2012-10-10 CA CA2853633A patent/CA2853633A1/en not_active Abandoned
- 2012-10-10 CN CN201280051004.1A patent/CN104010641B/zh not_active Expired - Fee Related
- 2012-10-10 AU AU2012329274A patent/AU2012329274B2/en not_active Ceased
- 2012-10-10 JP JP2014538819A patent/JP6095072B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012329274B2 (en) | 2016-11-10 |
| EP2753333A1 (en) | 2014-07-16 |
| AU2012329274A1 (en) | 2014-04-17 |
| WO2013062762A1 (en) | 2013-05-02 |
| CN104010641A (zh) | 2014-08-27 |
| CA2853633A1 (en) | 2013-05-02 |
| JP6095072B2 (ja) | 2017-03-15 |
| US20140194447A1 (en) | 2014-07-10 |
| US9169255B2 (en) | 2015-10-27 |
| EP2753333B1 (en) | 2017-06-21 |
| NZ623046A (en) | 2015-12-24 |
| EP2753333A4 (en) | 2015-01-28 |
| JP2014532643A (ja) | 2014-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104010641B (zh) | 用于治疗淀粉样蛋白病和共核蛋白病的含咖啡因的化合物和组合物 | |
| RU2501792C2 (ru) | Соединения, композиции и способы, предназначенные для лечения бета-амилоидных заболеваний и синуклеинопатий | |
| JP4568603B2 (ja) | アミロイド疾患およびシヌクレイノパチー（例えばアルツハイマー病、タイプ２型糖尿病、およびパーキンソン病）を処置するための化合物、組成物、および方法 | |
| US7919530B2 (en) | Compounds, compositions, and methods for the treatment of synucleinopathies | |
| EP1751097B1 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| US8916598B2 (en) | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies | |
| NZ623046B2 (en) | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies | |
| RU2799454C2 (ru) | Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение | |
| US20100331380A1 (en) | Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies | |
| US20150038591A1 (en) | Compounds, compositions and methods for the treatment of tauopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Washington State Applicant after: Tower pharmaceuticals Address before: Washington State Applicant before: Proteotech Inc. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170412 Termination date: 20171010 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |